Search

Displaying results 4861 - 4870 of 10000 in total
  1. Drug

    Pegdinetanib

    go.drugbank.com/drugs/DB05931
    Investigational

    CT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis

    Categories: Vascular Endothelial Growth Factor Receptor-2, antagonists & inhibitors
  2. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). … MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").

  3. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. … It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma [PMID: 21930686; PMID: 30107850; PMID: 27599039].

  4. Drug

    Beraprost

    go.drugbank.com/drugs/DB05229
    Investigational

    Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

  5. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. … Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration.

  6. Drug

    Setiptiline

    go.drugbank.com/drugs/DB09304
    Experimental

    In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.

  7. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    [A254222] Plasmepsins are aspartyl proteases produced by the malaria parasite _Plasmodium falciparum_, and PMX is considered to be essential for parasite egress and invasion. … UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria.

  8. Drug

    AdPEDF

    go.drugbank.com/drugs/DB05138
    Experimental

    It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors … AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD).

  9. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    These cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media. … These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability.

  10. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity … Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM).